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Aims: Individuals with diabetes and chronic kidney disease (CKD) are at high risk for renal
events. Recent trials of novel treatments have been negative, possibly because of variability in
response to treatment of the target risk factor. Atrasentan is a selective endothelin A receptor
antagonist that reduces urinary albumin-to-creatinine ratio (UACR), with a large variability
between patients. We are assessing its effect on renal outcomes in the Study Of diabetic
Nephropathy with AtRasentan (SONAR; NCT01858532) with an enrichment design (>30% lower-
ing of albuminuria) to select patients most likely to benefit.
Materials and Methods: SONAR is a randomized, double-blind, placebo-controlled trial with
approximately 3500 participants who have stage 2–4 CKD and macroalbuminuria and are receiv-
ing a maximum tolerated dose of a renin-angiotensin system inhibitor.
Results: After 6 weeks of exposure to atrasentan 0.75 mg once daily (enrichment period), par-
ticipants with ≥30% UACR decrease and no tolerability issues (responders) were randomly
assigned to placebo or atrasentan 0.75 mg/day. The responder group will be used for primary
efficacy and safety analyses. Approximately 1000 participants with <30% UACR reduction (non-
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responders) were also randomized to placebo or atrasentan. The primary endpoint is a composite
of a sustained doubling of serum creatinine or end-stage renal disease. The original power calcu-
lation indicated that a total of 425 primary renal events in the responder group provides 90%
power to detect a 27% reduction in relative risk (alpha level of .05).
Conclusion: SONAR aims to determine whether atrasentan added to guideline-recommended
therapies safely reduces the risk of CKD progression and delays the onset of end-stage renal
disease in patients with type 2 diabetes and nephropathy. SONAR also aims to establish
whether the enrichment of patients based on their initial “surrogate” response to atrasentan
will deliver a trial design in accord with personalized treatment of diabetic kidney disease.
KEYWORDS
atrasentan, diabetic kidney disease, endothelin receptor antagonist, personalized medicine,
randomized controlled clinical trial
1 | INTRODUCTION
Endothelin receptor antagonists (ERAs) represent a new approach
to reducing renal, and possibly cardiovascular (CV), risk in patients
with type 2 diabetes and kidney disease. ERAs are proven to be
effective in experimental models of progressive renal disease.1–3
Recent clinical studies have shown that the ERA atrasentan mark-
edly lowered urine albumin-to-creatinine ratio (UACR) in patients
with type 2 diabetes and kidney disease when added to a maxi-
mum tolerated dose of an angiotensin-converting enzyme (ACE)
inhibitor or angiotensin receptor blocker (ARB).4 These initial results
supported the conduct of a Phase 3 clinical outcome trial to deter-
mine whether atrasentan can delay or prevent progression to end-
stage renal disease (ESRD).
Many Phase 3 trials conducted over the past decade with other
new therapeutic agents for preventing loss of renal function failed to
demonstrate treatment benefit, despite each having shown promising
results in Phase 2 trials.5–10 In retrospect, some of these failures may
have been the result of deficiencies in trial design, including choice of
dose, patient selection, and a frequency of adverse effects that was
too high, reflecting known toxicity or “off-target” actions of the drugs
tested.11 To improve the likelihood of detecting a treatment effect, the
trial design should maximize the potentially beneficial effects of ther-
apy, while minimizing known adverse effects. In the case of an ERA,
this equates to maximizing UACR reduction while minimizing sodium
retention. Ideally, optimally balancing these pharmacologic actions prior
to randomization would mean enrolling only those individuals at high
risk of progressing to ESRD. This allows for selection of individuals at
high risk of disease (prognostic enrichment) who also demonstrate a
good response to study treatment (predictive enrichment).
With the above considerations in mind, the Study Of diabetic
Nephropathy with AtRasentan (SONAR) was designed to test the pos-
sible renoprotective effects of the ERA atrasentan in a prospective,
randomized, double-blind placebo-controlled clinical outcome trial in
patients at high risk of progressing to ESRD. The challenge was to
optimize the trial design, as outlined above, to identify the optimal
patient population, thereby maximizing the benefit: risk ratio of this
treatment. This paper describes such a strategy.
2 | MATERIALS AND METHODS
2.1 | Study objective
The primary objective of SONAR (NCT01858532; www.clinicaltrials.
gov) is to assess the efficacy and safety of atrasentan compared with
placebo in delaying the time to doubling of serum creatinine or the
onset of ESRD in participants with type 2 diabetes and chronic kid-
ney disease who are being treated with a maximum tolerated labeled
daily dose (MTLDD) of an ACE inhibitor or ARB. In addition, the
study is designed to assess the effects of atrasentan compared with
placebo on CV morbidity and mortality, changes in estimated glomer-
ular filtration rate (eGFR) and UACR, as well as on quality of life.
2.2 | Overall study design
SONAR is a multinational, multicentre, randomized, double-blind,
parallel-group, placebo-controlled trial assessing the effects of atrasen-
tan on renal outcomes in individuals with type 2 diabetes and nephropa-
thy. A total of 3668 participants have been randomized at 795 sites in
41 countries (Figure 1). The overall study design is presented in Figure 2.
2.3 | Study population
The study population includes patients with type 2 diabetes mellitus with
an eGFR of 25–75 mL/min/1.73 m2, a UACR ≥300 mg/g creatinine and
<5000 mg/g, and brain natriuretic peptide (BNP) ≤200 pg/mL. Addi-
tional inclusion and exclusion criteria are reported in Table 1.
2.4 | Study periods
2.4.1 | Screening, run-in and enrichment
Study participants who meet all inclusion and no exclusion criteria pro-
ceed directly to the run-in period to optimize ACE inhibitor/ARB and/or
diuretic doses. Subsequently, eligible participants enter the enrichment
period and receive atrasentan 0.75 mg once daily. The rationale of using
this atrasentan dose has been described in previous publications.4,12 The
6-week enrichment period, a unique feature of the SONAR study design,
was used to select participants who have a significant response to
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atrasentan (≥30% reduction in UACR) without adverse effects, such as
significant sodium and fluid retention (eg, weight gain >3 kg and BNP
≥300 pg/mL). The enrichment phase of the SONAR trial does not
include a placebo arm. Thus, placebo-controlled inferences about the
effect of atrasentan during this stage cannot be made.
2.4.2 | Randomization
Approximately 2500 “responders” (UACR reduction ≥30% from base-
line) will be randomized 1:1 to atrasentan 0.75 mg/day or matching
placebo. These participants will comprise the primary intention-to-
treat (ITT) population for assessing the safety and efficacy of atrasen-
tan. In addition, a selection of approximately 1000 “non-responders”
(UACR reduction <30% from baseline) will be randomized to double-
blind treatment in a parallel study stratum. Enrollment of 1000 non-
responders will be distributed chronologically to provide an experi-
ence similar to that of responders (ie, comparable exposures, balancing
enrollment across geographic regions). The rationale for the random-
ized non-responder cohort is to undertake an additional analysis to
determine whether longer-term exposure to atrasentan can also delay
progression of renal disease in participants with a modest UACR
reduction on initial exposure to study drug. Randomization was per-
formed centrally through an interactive voice response system on the
basis of a computer-generated randomization schedule prepared by
the study sponsor. A stratified randomization scheme ensures balance
in treatment allocation within geographic regions, baseline UACR
levels (≤ or >1000 mg/g), and categories of UACR reduction achieved
during the enrichment period (30% – <45%, 45% – <60% and ≥60%,
respectively). Participants and all study personnel (with the exception
of the Independent Data Monitoring Committee) are kept masked to
treatment allocation and study drug; atrasentan and placebo are pack-
aged identically, with uniform capsule appearance, labeling, appear-
ance and odor, as well as administration schedule.
2.4.3 | Double-blind treatment, follow-up and
management of participants
After randomization, telephone contacts are scheduled at 1- and
2-week time intervals, followed by in-person visits at 1 and 3 months
and at 3-month intervals thereafter. Each follow-up visit includes
assessment for primary outcomes, adverse events, concomitant ther-
apies, study drug adherence and accountability, and provision of fur-
ther study medication. In addition, vital signs are recorded,
participants are examined for peripheral edema, and blood and urine
are collected for laboratory measurements. Participants receive the
study drug until they reach renal replacement therapy (dialysis or
renal transplantation), discontinue the study drug or prematurely
withdraw from the study. Upon study drug discontinuation, partici-
pants are to have a follow-up visit 45 days after the last dose of
study drug to assess the effects of discontinuing the study drug. Par-
ticipants who prematurely discontinue the study drug but do not ter-
minate the study are to continue follow-up visits as scheduled; if this
is not possible, they are asked to allow follow-up via phone, family or
treating doctors.
FIGURE 1 Countries participating in
SONAR. Study Of diabetic Nephropathy
with AtRasentan
Enrichment
Period
(6 weeks)
Atrasentan
0.75 mg QD
Screening
Period
(up to
14 days) 
STOP
Double-Blind Treatment Period
Run-in Period
2 weeks if receiving MTLD
of RAS inhibitor
<30%
UACR
reduction
≥30%
UACR
reduction
Run-in Period
4–12 weeks if not
receiving MTLD of RAS
inhibitor
Weight gain >3 kg
BNP >300 pg/mL
Placebo QD
n=1000
Placebo QD
Atrasentan 0.75 mg QD
Follow-up
Period
(45 days)
Atrasentan 0.75 mg QD
n=2500
FIGURE 2 SONAR study diagram. MTLD,
maximum tolerated labeled dose; QD, once
daily; RAS, renin-angiotensin system;
SONAR, Study Of diabetic Nephropathy
with AtRasentan; UACR, urinary albumin-
to-creatinine ratio
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2.5 | Outcome definitions and event adjudication
Primary efficacy analysis will be conducted in the responder group
(Figure 2). The primary outcome for evaluation of the effect of atrasentan
on delaying progression of renal disease is the time to first occurrence of
any of the following components of the composite renal endpoint: dou-
bling of serum creatinine (confirmed by a second serum creatinine mea-
surement at least 30 days later), onset of ESRD or renal death (Table 2).
Renal death is defined as death attributable to kidney failure (ie, necessity
of dialysis/renal transplantation, without dialysis or transplantation avail-
able or implemented). A blinded and independent event adjudication com-
mittee (EAC), consisting of experts in nephrology, cardiology and
neurology, will adjudicate primary and secondary endpoints. For the pur-
pose of event adjudication, ESRD is defined as the necessity of mainte-
nance dialysis (peritoneal or hemodialysis) > 90 days, renal transplantation
or sustained eGFR <15 mL/min/1.73m2 for >90 days. The 90-day crite-
rion is included in the definition of the ESRD endpoint to avoid misclassi-
fication of ESRD caused by acute kidney injury or volume overload
requiring renal replacement therapy (RRT). If ESRD is reached <90 days
before study closure, or if the participant dies within 90 days of dialysis
initiation, the EAC will adjudicate whether the endpoint meets ESRD cri-
teria, using the detailed definitions and criteria defined in the EAC charter.
Secondary and exploratory efficacy endpoints are described in Table 2.
2.6 | Background medication
All efforts are to be undertaken to maintain participants’ stable doses
of ACE inhibitors/ARBs and diuretics during the double-blind
TABLE 1 Main inclusion and exclusion criteria of SONAR
Inclusion criteria
Criteria for entry into the study
18–85 years of age
History of type 2 diabetes and receiving at least 1 anti-diabetic
medication
Criteria for entry into the run-in period
Estimated GFR 25–75 mL/min/1.73 m2
UACR ≥300 and <5000 mg/g (≥34 mg/mmol and <565 mg/mmol)
BNP ≤ 200 pg/mL (200 ng/L)
Systolic blood pressure ≤ 180 mm Hg and ≥110 mm Hg
Criteria for entry into the enrichment period (open-label atrasentan
treatment)
Stable treatment with an ACE inhibitor and/or ARB for at least
4 weeks prior to and during screening
Criteria for entry into the double-blind treatment:
≥30% reduction in UACR from the beginning of the enrichment visit
to the end (atrasentan responders)
<30% reduction in UACR from the beginning of the enrichment
visit to the end (atrasentan non-responders)
No more than 3-kg weight gain during enrichment and absolute
serum BNP not ≥300 pg/mL (300 ng/L) at the last enrichment
visit
No more than 0.5-mg/dL increase in serum creatinine (48 μmol/L)
and no more than 20% increase from the beginning of enrichment
to the end
RAS inhibitor at the MTLDD during enrichment with no dose
adjustments
Participant has taken a diuretic at any dose unless medically
contraindicated
Exclusion criteria
Type 1 diabetes mellitus
History of severe peripheral edema or facial edema requiring
diuretics unrelated to trauma or a history of myxedema
History of pulmonary hypertension, pulmonary fibrosis or any lung
disease requiring oxygen therapy
Documented diagnosis of heart failure, previous hospitalization for
heart failure, or current or constellation of symptoms (dyspnea on
exertion, pedal edema, orthopnea) indicative of heart failure
Known non-diabetic kidney disease
Elevated liver enzymes (serum ALT and/or serum AST) > 3 times the
upper limit of normal
Hemoglobin <9 g/dL
Sensitivity to loop diuretics
Clinically significant CVD or CAD within 3 months of the screening S1
visit, defined as 1 of the following:
• Hospitalization for MI or unstable angina; or
• New onset angina with positive functional study or coronary
angiogram revealing stenosis; or
• Coronary revascularization procedure; or
• TIA or stroke
Significant comorbidities (malignancies, liver disease) with life
expectancy <1 year
Female participants who are premenopausal, defined as any female
participant with a menses in the past 2 years
Abbreviations: ACE, angiotensin converting enzyme; ALT, alanine amino-
transaminase; ARB, angiotensin receptor blocker; AST, aspartate amino-
transaminase; BNP, brain natriuretic peptide; CAD, coronary artery
disease; CVD, cerebrovascular disease; GFR, glomerular filtration rate; MI,
myocardial infarction; MTLDD, maximum tolerated labeled daily dose;
RAS, renin-angiotensin system; SONAR, Study Of diabetic Nephropathy
with AtRasentan; TIA, transient ischemic attack; UACR, urinary albumin-
to-creatinine ratio.
TABLE 2 Primary, secondary and exploratory endpoints of SONAR
1 Primary composite endpoint:
1. Time to doubling of serum creatinine from baseline (confirmed
by 30-day serum creatinine)
2. Time to ESRD defined as eGFR <15 mL/min/1.73 m2, need for
chronic dialysis (both confirmed after 90 days), renal
transplantation or renal death
2 Secondary endpoint:
1. Time to a 50% eGFR reduction
2. Time to cardio-renal composite endpoint: doubling of serum
creatinine, ESRD, CV death, non-fatal MI, non-fatal stroke
3. Time to first occurrence of a component of composite renal
endpoint: doubling of serum creatinine or the onset of ESRD
for all randomized participants (responders and non-
responders)
4. Time to the CV composite endpoint: CV death, non-fatal MI,
and non-fatal stroke
3 Additional endpoints include (but not limited to):
1. Time to 40% reduction in eGFR (from values at randomization
and 3 months post randomization)
2. Change in eGFR slope (from values at randomization and
3 months post randomization)
3. Change in eGFR (from values at randomization and 3 months
post randomization) to 45 days after end of treatment
4. Change from baseline (from values at randomization) to
24 months post-randomization visit on UACR
5. Time to major vascular event: CV death, non-fatal MI, non-fatal
stroke, hospitalized unstable angina
6. Time to congestive heart failure (hospitalized and non-
hospitalized)
Abbreviations: CV, cardiovascular disease; eGFR, estimated glomerular fil-
tration rate; ESRD, end-stage renal disease; MI, myocardial infarction;
SONAR, Study Of diabetic Nephropathy with AtRasentan; UACR, urinary
albumin-to-creatinine ratio.
1372 HEERSPINK ET AL.
treatment period throughout the study. If at any time during the
study there is an interruption of or decrease in ACE inhibitor/ARB
dose, resumption of the previous dose is attempted within 1 month,
in line with the investigator’s medical judgment. ERAs may induce
sodium retention in some patients.13,14 The investigator may increase
the diuretic dose as needed in the presence of signs and symptoms
of fluid overload (eg, peripherial edema, dyspnea or orthopnea). Man-
agement of glucose, blood pressure or lipid-lowering medications,
and of other therapies is at the discretion of the investigator, accord-
ing to local and/or international clinical practice guidelines.
2.7 | Statistical considerations
2.7.1 | Estimating risk reduction
Sample size for the double-blind treatment period is based on the
expected rate of the primary efficacy endpoint and the anticipated
size of the effect of treatment with atrasentan. In the Phase 2 RADAR
trial, 51% of participants receiving atrasentan 0.75 mg/day achieved
a ≥30% reduction in UACR. In this population, the mean UACR
reduction was 54%, which is expected to reduce the risk of ESRD by
up to 50%, based on the association between drug-induced reduc-
tions in UACR and risk changes in ESRD.15 However, because the
confidence intervals are large for this level of UACR reduction, a con-
servative effect size of 27% risk reduction in ESRD was chosen, using
the lower boundary of the confidence interval. A modeling and simu-
lation analysis, taking into account all other effects of atrasentan on
renal and CV risk markers, confirmed that a 27% reduction in renal
risk is highly plausible.12 A total of 425 events are required to detect
a 27% reduction in risk (hazard ratio, 0.73), with 90% power at a
two-sided alpha level of .05. The size of the non-responder popula-
tion is based on logistical and feasibility grounds.
During the course of the study, and after all patients had com-
pleted the enrichment period and were randomized into the study, it
became apparent that the observed renal event rate in the atrasentan
responder population was lower than originally expected. The very
lengthy follow-up that would be required to collect the original
425 planned primary events led to the sponsor’s decision not to con-
tinue with ongoing follow-up. Clinical trial sites were notified accord-
ingly in late 2017. At the time the trial was discontinued, more than
121 renal events were projected to be accumulated, resulting in more
than 90% power to detect a hazard ratio of 0.55, and more than 80%
power to detect a hazard ratio of 0.60.
2.7.2 | Efficacy assessment, primary analysis
The primary efficacy analysis will be based on the ITT population,
defined as all randomized participants in the responder group. The
primary analysis will employ Cox proportional hazards regression to
estimate the hazard ratio (and 95% confidence interval) of atrasentan
to placebo; this will be adjusted based on relevant covariates (ie,
UACR, eGFR, age and serum albumin). For determination of doubling
of serum creatinine, values obtained prior to the enrichment period
will be used as reference baseline values. Statistical tests for treat-
ment comparisons will be performed using a stratified log-rank test,
adjusting for the stratification factors used at randomization.
2.7.3 | Secondary efficacy assessment according to urine
albumin-to-creatinine ratio response stratification
As it remains unknown whether the enrichment by albuminuria
response is actually delivering better renal protection, which is the
hypothesis tested in the SONAR trial, we are also enrolling 1000
non-responder participants, in whom the effect of atrasentan on
renal outcome will be assessed. A weighted, pooled analysis of the
responders and non-responders will provide an assessment of the
treatment effect in the combined patient population as a secondary
objective of the study. At the randomization visit, participants are
randomized in different UACR response strata: <0%, 0% – <15% and
15% – <30% in non-responders; 30% – <45%, 45% – <60% and
≥60% in the responder population. This stratification by UACR
response levels should enable identification of a minimum UACR
response threshold that is associated with a beneficial effect of atra-
sentan on the primary renal endpoint.
2.7.4 | Safety assessment
The frequency and intensity of, and the relationship with, treatment-
emergent adverse events and serious adverse events will be deter-
mined in all participants exposed to study medication during the
enrichment and double-blind treatment periods. As ERAs may cause
sodium retention, adverse events related to fluid retention, including
edema and congestive heart failure, are carefully monitored. In addi-
tion, weight measurements are performed at each visit during the
study, preferably under the same circumstances. Results are com-
pared with those of previous visits. If there is an increase in body
weight ≥2 kg, measurements error should be ruled out, presence of
edema should be evaluated, and the dose of the diuretic should be
re-evaluated and adjusted if necessary. Other adverse events of spe-
cial interest include vasodilatation (eg, hypotension, headache, nasal
congestion, hot flushes), CV toxicity and liver toxicity. Acute kidney
injury will be monitored, diagnosed and treated as suggested in the
KDIGO Clinical Practice Guideline for Acute Kidney Injury.16 Other
safety assessments include physical examination, vital sign measure-
ments, 12-lead electrocardiograms and centrally analysed laboratory
measurements.
2.7.5 | Patient-reported outcomes
Health-related quality-of-life outcomes, using the EuroQol 5 Dimen-
sions 5 Levels (EQ-5D-5L) index score, Assessment of Quality of Life
(AQOL)-4D (Australia only) and Kidney Disease Quality of Life ques-
tionnaires, are assessed at baseline and every 3 months during the
first year of the trial, and at yearly intervals thereafter.
2.8 | Role of funding source
The study is overseen by a steering committee, including non-voting
members from the sponsor. The steering committee designed the
study, and it oversees the conduct of the trial and the analysis of all
data. The sponsor is responsible for collection and analysis of data, in
conjunction with the steering committee. All authors will have access
to study results.
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3 | DISCUSSION
Endothelin-1 (ET-1) is recognized as an important drug target in dia-
betic kidney disease. Elevated renal ET-1 levels in diabetic kidney dis-
ease are thought to contribute to renal vasoconstriction, glomerular
cell dysfunction and proteinuria through activation of renal type A
endothelin (ETA) receptors.17 ETA receptor blockade attenuates pro-
gression of nephropathy in experimental models of diabetic kidney
disease by improving glomerular function17,18 and by attenuating
inflammatory pathways.2
A previous trial with a different ERA showed that avosentan at
doses of 25 and 50 mg/day markedly reduced UACR but increased
the risk of heart failure and mortality, leading to early termination of a
large outcome trial.5,19 That study highlighted the importance
of careful dose selection, to focus not only on the protective effect of
the study drug, but also on drug-related adverse outcomes (eg, sodium
retention). Our previous dose-finding study with the ERA atrasentan,
which is highly selective for ETA, showed that a low dose (0.75 mg/
day) of atrasentan had a significant UACR-lowering effect and led to
minimal signs of sodium retention.4 This study also showed that the
extent of UACR lowering with atrasentan did not correlate with the
degree of fluid retention. This allowed us to select a potentially opti-
mal atrasentan dose and to identify a responder population with a
substantial UACR reduction but with minimum sodium retention.12
SONAR, like other renal outcome trials in diabetic kidney disease,
will examine the effect of the study drug on the “standard” composite
renal endpoint in a population at high renal and CV risk. However, in
contrast to other trials, it employs a response enrichment design. The
rationale for introducing this enrichment strategy is to enhance the
selection of patients who would benefit most and exclude those
unlikely to benefit from the drug. Indeed, analyses from past trials
in diabetic kidney disease confirmed a large patient heterogeneity in
drug response, both in effects that lead to organ protection and in
effects that lead to organ failure, highlighting the need to exclude the
specific subgroup of patients in which the drug is not effective, and
possibly even harmful.20–23 The inclusion of patients who are more
likely to show benefit (enrichment) maximizes the chance of identify-
ing and registering a new beneficial drug for a complex disease such
as diabetic kidney disease. As many drugs have failed in late-stage
drug development,24 this enrichment design is a potential way to
make the drug development trajectory more successful and efficient.
It also represents a step in the direction of personalized medicine.
The results from a predictive enrichment trial may apply only to
the selected “responder” patient subgroup and may not be extrapo-
lated to the broader population. While this may complicate general
statements on drug efficacy and safety, it should not be interpreted
as a limitation of the enrichment design. Clinical outcome trials that
are conducted for the purpose of registering a new drug for use in
clinical practice should represent the way the drug is used in daily
practice. In clinical practice, drug treatment will commonly be discon-
tinued if patients do not show a good response, and especially if
patients develop side effects. The enrichment design of SONAR thus
mimics clinical practice and may more reliably represent how the drug
is used in practice, and it is in accord with the concept of personal-
ized medicine for the treatment of diabetic kidney disease.
The enrichment design may have disadvantages. The impact on
the intended study population of enrichment of the population based
on a biomarker response is unknown. For example, by selecting
patients based on their albuminuria response, the selected population
may be at a lower renal risk, which could explain the low renal event
rate observed in the SONAR trial. Alternatively, the low renal event
rate could also be explained by the larger than anticipated treatment
effect. The enrichment results, which are described in the accompa-
nying SONAR article, actually show that atrasentan lowers UACR by
nearly 50% in the responder population, raising the possibility of a
very large renoprotective effect.25
Validated surrogate outcomes can facilitate the conduct of clini-
cal trials in diabetic kidney disease and, ultimately, targeted patient
care. There is an ongoing debate as to whether UACR is a valid surro-
gate of renal outcomes, because of the paucity of prospective clinical
trials showing that short-term treatment effects on albuminuria pre-
dict long-term reduction in renal outcomes. Some claim that the fail-
ure of past trials is explained by the fact that albuminuria reduction is
a poor surrogate for clinical renal outcomes. The alternative view is
that multiple clinical trials have shown, albeit in post hoc analyses,
that drug-induced reductions in albuminuria precede and predict
long-term renoprotection, independently of the drug or population
studied, and that lack of prediction in some trials is based on other
drug effects offsetting the potential benefit of albuminuria reduc-
tion.26 As randomization into the SONAR trial is stratified based on
the UACR-lowering response, SONAR is designed to allow assess-
ment, in a scientifically robust, prospective, blinded, placebo-
controlled manner, of whether a drug-induced reduction in UACR is
an independent predictor of long-term renoprotection. Thus, SONAR
is expected to help in establishing UACR as a valid surrogate marker
in future diabetic kidney disease trials.
In conclusion, an important lesson learned from all clinical trials
conducted in the past decade in diabetic kidney disease is that ignoring
individual drug response results in suboptimal patient selection and the
failure of drug development programmes. SONAR, with its enrichment
design, may establish a new precedent for clinical trials in diabetic kid-
ney disease, and will define the effect of atrasentan on renal outcomes
that are considered to be of clinical and regulatory importance in a
population at high risk of progressive renal dysfunction and CV events.
3.1 | Members of the SONAR Steering Committee
Dick de Zeeuw (Chair), Hans-Henrik Parving (co-chair), George Bakris,
Ricardo Correa-Rotter, Hiddo J. L. Heerspink, Fan Fan Hou, Donald
Kohan, Dalane Kitzman, Hirofumi Makino, John McMurray, Vlado
Perkovic, Sheldon W. Tobe, Dennis Andress, John J. Brennan (until
November 2016), Blai Coll, Mark Houser (AstraZeneca, former
employee of AbbVie), Melissa Wigderson, Joel Melnick (AbbVie,
starting November 2016).
3.2 | Members of the SONAR Independent Data
Monitoring Committee
Peter McCullough (Chair), John Lachin, Johannes Mann, Charles
Herzog, Rudolph Bilous, David Webb, Mitchell Rosner.
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3.3 | Members of the SONAR Event Adjudication
Committee
Rajiv Agarwal (Chair until December 2015), Dalane Kitzman (Chair
from January 2016), Michael Rocco, Chirag Parikh, Daniel Kolansky,
Scott Kasner, Brett Kissela, Kausik Ray, Mihai Gheorghiade, Stephen
Seliger, Philip Gorelick, James Januzzi (from July 2017).
3.4 | National coordinators
Argentina, Laura Maffei and Walter Douthat; Australia, Carol Pollock,
Simon Roger and Muh Geot Wong; Austria, Gert Mayer; Belgium, Luc
Van Gaal (until January 2015); Brazil, Maria Tereza Zanella and
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